Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (81-90 of 274) with videos related to

Pageof 28
Sort By:
Cancer|April 25, 2008
Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designsBart Barlogie, Jeff Haessler, Mauricio Pineda-Roman, et al.
Blood|July 26, 2014
CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone diseaseSarah K Johnson, James P Stewart, Rakesh Bam, et al.
British Journal of Haematology|September 12, 2018
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial dataDeanna E Morra, Sheila K Pierson, Dustin Shilling, et al.
Cancer|October 15, 2010
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsSarah Waheed, John D Shaughnessy, Frits van Rhee, et al.
Experimental Hematology|February 26, 2013
NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activitySathisha Upparahalli Venkateshaiah, Sharmin Khan, Wen Ling, et al.
Blood|February 4, 2010
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBijay Nair, Frits van Rhee, John D Shaughnessy, et al.
Ejhaem|May 19, 2023
Variability of definition of high-risk multiple myeloma across phase III clinical trialsFaris Jamal Abu Za'nouneh, Obada Ababneh, Carolina Schinke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myelomaChoon-Kee Lee, Bart Barlogie, Nikhil Munshi, et al.
Cytotherapy|December 22, 2010
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103Amberly Moreno-Bost, Susann Szmania, Katie Stone, et al.
BMC Cancer|July 8, 2018
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myelomaYa-Wei Qiang, Shiqiao Ye, Yuhua Huang, et al.
Pageof 28

Showing results (81-90 of 274) with videos related to

Sort By:
Pageof 28
Cancer|April 25, 2008
Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designsBart Barlogie, Jeff Haessler, Mauricio Pineda-Roman, et al.
Blood|July 26, 2014
CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone diseaseSarah K Johnson, James P Stewart, Rakesh Bam, et al.
British Journal of Haematology|September 12, 2018
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial dataDeanna E Morra, Sheila K Pierson, Dustin Shilling, et al.
Cancer|October 15, 2010
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsSarah Waheed, John D Shaughnessy, Frits van Rhee, et al.
Experimental Hematology|February 26, 2013
NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activitySathisha Upparahalli Venkateshaiah, Sharmin Khan, Wen Ling, et al.
Blood|February 4, 2010
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBijay Nair, Frits van Rhee, John D Shaughnessy, et al.
Ejhaem|May 19, 2023
Variability of definition of high-risk multiple myeloma across phase III clinical trialsFaris Jamal Abu Za'nouneh, Obada Ababneh, Carolina Schinke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myelomaChoon-Kee Lee, Bart Barlogie, Nikhil Munshi, et al.
Cytotherapy|December 22, 2010
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103Amberly Moreno-Bost, Susann Szmania, Katie Stone, et al.
BMC Cancer|July 8, 2018
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myelomaYa-Wei Qiang, Shiqiao Ye, Yuhua Huang, et al.
Pageof 28